HanAll BioPharma Co., Ltd.
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 1973-11-20
- Employees
- -
- Market Cap
- -
- Website
- http://www.hanall.co.kr
Clinical Trials
16
Trial Phases
4 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (16 trials with phase data)• Click on a phase to view related trials
Efficacy and Safety of Leuprolide Acetate 45 mg in Subjects With Central Precocious Puberty
- Conditions
- CPP
- Interventions
- Drug: Eligard® 45 mg
- First Posted Date
- 2025-04-15
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- HanAll BioPharma Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT06926933
- Locations
- 🇰🇷
Korea University Ansan Hospital, Ansan, Korea, Republic of
🇰🇷Jeonbuk National University Hospital, Jeonju, Korea, Republic of
🇰🇷Chosun University Hospital, Kwangju, Korea, Republic of
A Study to Evaluate the Efficacy and Safety of Tanfanercept (HL036) in Dry Eye Disease
- First Posted Date
- 2024-05-06
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- HanAll BioPharma Co., Ltd.
- Target Recruit Count
- 750
- Registration Number
- NCT06400589
- Locations
- 🇺🇸
HanAll Site #1, Delray Beach, Florida, United States
A Study Assessing the Safety of Oral ATH-399A in Healthy Adult Participants
- First Posted Date
- 2023-10-18
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- HanAll BioPharma Co., Ltd.
- Target Recruit Count
- 76
- Registration Number
- NCT06088784
- Locations
- 🇨🇦
Syneos Quebec Canada, Quebec, Canada
A Study to Assess the Efficacy and Safety of Tanfanercept (HL036) Ophthalmic Solution in Participants With Dry Eye
- Conditions
- Dry Eye
- Interventions
- Drug: PlaceboDrug: 0.25% Tanfanercept Ophthalmic Solution
- First Posted Date
- 2021-11-05
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- HanAll BioPharma Co., Ltd.
- Target Recruit Count
- 260
- Registration Number
- NCT05109702
- Locations
- 🇺🇸
Cornea & Cataract Consultants of Arizona, Phoenix, Arizona, United States
🇺🇸Global Research Management, Glendale, California, United States
🇺🇸Eye Research Foundation, Inc., Newport Beach, California, United States
A Study to Assess Efficacy and Safety of HL036 in Subjects With Dry Eyes
- Conditions
- Dry Eye
- First Posted Date
- 2019-02-19
- Last Posted Date
- 2022-04-14
- Lead Sponsor
- HanAll BioPharma Co., Ltd.
- Target Recruit Count
- 637
- Registration Number
- NCT03846453
- Locations
- 🇺🇸
Cornea and Cataract Consultants of Arizona, Phoenix, Arizona, United States
🇺🇸Eye Research Foundation, Newport Beach, California, United States
🇺🇸East West Eye Institute, Torrance, California, United States
- Prev
- 1
- 2
- 3
- 4
- Next